ALTSTATION.IO

Pfizer Inc. (PFE) Stock Analysis

By Nova Skye | AltStation.io | Updated October 12, 2026

Price

$28.41

Change

+0.48%

Market Cap

$161.96B

Avg Volume

36.1M

Company Overview

Pfizer Inc. is a global pharmaceutical heavyweight headquartered in New York, United States, operating within the healthcare sector as a general drug manufacturer. Founded in 1849, the company develops, produces, and distributes prescription drugs, vaccines, biosimilars, and sterile injectables to healthcare systems, pharmacies, and patients worldwide. Its operations run across three distinct segments: Biopharma, PC1, and Pfizer Ignite. The commercial portfolio spans high-volume cardiovascular treatments like Eliquis and infectious disease therapies like Paxlovid to major oncology assets like Ibrance and Padcev.

Pfizer operates as an established market leader with unmatched global distribution and deep clinical reach. Its main competitive edge lies in high-value therapeutic areas like rare diseases, immunology, and oncology, reinforced by co-development agreements with Bristol-Myers Squibb, Astellas Pharma, and BioNTech. The primary threat to its base business remains patent expirations and fierce competition across mature therapeutic categories. Pfizer defends its position by expanding a broad portfolio of biosimilars and deploying complex, high-barrier therapies such as antibody-drug conjugates and bispecifics.

Right now, the company is executing a clear strategic pivot toward precision oncology and tech-driven drug discovery. A notable recent milestone is its collaboration with Boltz, PBC to develop and deploy biomolecular artificial intelligence foundation models. At the same time, Pfizer is expanding specialized cancer brands like Adcetris, Tivdak, and Elrexfio to build out durable revenue streams. The strategy is direct: replace legacy volume by prioritizing targeted, high-margin therapeutics and faster computational pipeline development.

Key Financials

Market Cap

$161.96B

Revenue

$63.70B

EBITDA

$25.38B

Gross Margin

74.7%

Profit Margin

6.8%

Revenue Growth

2.6%

Total Cash

$11.70B

Total Debt

$63.48B

Free Cash Flow

$12.49B

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

37.39

Forward P/E

9.80

Beta

0.28

52-Week High

$29.21

52-Week Low

$23.62

EPS

$0.76

50-Day Avg

$27.62

200-Day Avg

$26.46

Price/Book

1.90

Technical Analysis

PFE trades at $28.41, 86% of the way from its 52-week low of $22.57 to its 52-week high of $29.21. The stock is 3.18% below that high and 25.31% above the low. Price sits 1.03% above the 20-day moving average of $27.99, with momentum of 1.73% over five trading days and 2.02% over 20 trading days. Near-term support is $27.41, while resistance is $29.02. The trend is positive, but PFE is approaching resistance after already moving near the top of its annual range.

Recent News and Developments

FDA expands TUKYSA into front-line metastatic breast cancer

The FDA approved TUKYSA with trastuzumab and pertuzumab as maintenance treatment for adults with unresectable locally advanced or metastatic HER2-positive breast cancer. Median progression-free survival reached 24.9 months with TUKYSA versus 16.3 months with placebo, an 8.6-month improvement. Source: Pfizer

Analysts raise Pfizer targets without upgrading the stock

Scotiabank raised its Pfizer target from $30 to $33, Cantor Fitzgerald moved from $27 to $28, and JPMorgan increased its target from $28 to $30. Their ratings stayed at Sector Outperform, Neutral, and Neutral, respectively. Source: Benzinga

Pfizer declares its 352nd consecutive quarterly dividend

Pfizer declared a fourth-quarter dividend of $0.43 per share, payable December 7 to shareholders of record on November 6. This will be the company’s 352nd consecutive quarterly dividend. Source: Pfizer

Market Sentiment and Analyst Recommendations

Bull Case

Pfizer generated $63.70 billion in revenue, and revenue growth is positive at 2.6%. The FDA approval expanding TUKYSA into front-line metastatic HER2-positive breast cancer gives the company another commercial growth driver. Median progression-free survival reached 24.9 months with TUKYSA versus 16.3 months with placebo, an improvement of 8.6 months. Analysts remain constructive, with a buy recommendation based on 26 analysts and a consensus target of $29.26. The most optimistic target is $36.00, while Scotiabank raised its target from $30 to $33 and JPMorgan moved from $28 to $30. Pfizer also declared a fourth-quarter dividend of $0.43 per share, its 352nd consecutive quarterly dividend. Investors would buy PFE here for its durable revenue base, expanding oncology portfolio, dividend record, and potential upside toward the higher analyst targets.

Bear Case

PFE is not obviously cheap at 37.39 times earnings. The stock already trades at $28.41, close to the $29.26 consensus analyst target and just 3.18% below its 52-week high. Near-term resistance at $29.02 could limit additional upside unless the business produces stronger results. Revenue growth of 2.6% is positive but modest relative to the current earnings multiple. Pfizer carries $63.48 billion in total debt against $11.70 billion in total cash, creating a significant balance-sheet burden. The analyst target range starts at $25.00, showing that some forecasts imply downside from the current price. Recent target increases also came without ratings upgrades from Scotiabank, Cantor Fitzgerald, or JPMorgan, which suggests analysts see incremental improvement rather than a major change in the thesis.

What to Watch

The first technical test is whether PFE can break above near-term resistance at $29.02 and then challenge the 52-week high of $29.21. A move below the 20-day moving average of $27.99 would weaken the current positive setup, while $27.41 is the key near-term support level. Investors should track whether five-day momentum of 1.73% and 20-day momentum of 2.02% remain positive. Commercial adoption of the newly approved TUKYSA maintenance regimen is the clearest product catalyst, especially after the reported 24.9-month median progression-free survival result. Revenue growth needs to improve beyond 2.6% to better support a P/E of 37.39. The $0.43 dividend is payable December 7 to shareholders of record on November 6, making those the next specific shareholder dates provided. The thesis strengthens if price clears $29.21 alongside improving growth and weakens if PFE loses $27.41 while growth remains at 2.6%.

Analyst Consensus

BUY

Based on 26 analyst opinions

Low Target

$25.00

Mean Target

$29.26

High Target

$36.00

Earnings and Financial Data

Sector

Healthcare

Industry

Drug Manufacturers – General

Employees

75,000

Earnings & Dividends

Next Earnings

Nov 03, 2026

EPS (Trailing)

$0.76

Dividend Yield

608.0%

Payout Ratio

226.3%

Frequently Asked Questions

Is PFE a good stock to buy?

The analyst recommendation is buy based on 26 analysts, and PFE has positive five-day and 20-day momentum of 1.73% and 2.02%. The takeaway is that sentiment and momentum are positive, but the stock is already 86% of the way through its 52-week range.

What is PFE’s price target?

The analyst target is $29.26, with estimates ranging from $25.00 to $36.00. The takeaway is that analyst expectations vary widely around the current $28.41 price.

What are PFE’s support and resistance levels?

Near-term support is $27.41, and near-term resistance is $29.02. The takeaway is that these are the key 30-day price thresholds to monitor.

Is PFE near its 52-week high?

PFE is priced at $28.41, which is 3.18% below its technical 52-week high of $29.21. The takeaway is that the stock is trading close to the top of its annual range.

Is Pfizer growing revenue?

Pfizer reports $63.70 billion in revenue with revenue growth of 2.6%. The takeaway is that revenue is growing, but the current growth rate is modest.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated October 12, 2026.